Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response.

Robert J Norgard Pratha Budhani Sarah A O'Brien Youli Xia Jessica N Egan Brianna Flynn Joshua R Tagore Joseph Seco Gregory W Peet Ania Mikucka Ruby Wasti Li-Chuan Chan Melanie Hinkel Sandra Martinez-Morilla Jeanine Pignatelli Francesca Trapani Emily Corse Di Feng Kaja Kostyrko Marco H Hofmann Kang Liu Abhishek S Kashyap

Published in: Cancer research communications (2024)

Combination of SOS1 and MEK inhibitors increase T cell infiltration while blunting pro-immune myeloid cell maturation and highlights the need for combining KRAS cancer-targeted therapy with myeloid activation to enhance and prolong anti-tumor effects.

Keyphrases

dendritic cells
bone marrow
acute myeloid leukemia
papillary thyroid
pi k akt
single cell
cell therapy
anti inflammatory
squamous cell carcinoma
lymph node metastasis
mesenchymal stem cells
wild type